Erin Nuzzo1, Katherine M Berg2, Lars W Andersen3,4, Julia Balkema3, Sophia Montissol3, Michael N Cocchi3,5, Xiaowen Liu3, Michael W Donnino2,3. 1. 1 Department of Internal Medicine. 2. 2 Division of Pulmonary, Critical Care, and Sleep, and. 3. 3 Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 4. 4 Department of Anesthesiology, Aarhus University Hospital, Aarhus, Denmark; and. 5. 5 Anesthesia, and Critical Care, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Abstract
RATIONALE: Rodent studies have shown that pyruvate dehydrogenase (PDH) levels are low in sepsis. This may cause cells to shift to anaerobic metabolism, resulting in increased lactate production. Alterations in PDH during sepsis have never been studied in humans. OBJECTIVES: The objective of this pilot study was to measure PDH activity and quantity in patients with severe sepsis. METHODS: We conducted a pilot case-control study at a single urban tertiary care center. We compared PDH activity and quantity between patients with severe sepsis admitted to the intensive care unit and healthy control subjects. PDH activity and quantity were measured in isolated peripheral blood mononuclear cells. We measured PDH activity and quantity in control subjects at baseline and in patients with sepsis at 0 (baseline), 24, 48, and 72 hours. MEASUREMENTS AND MAIN RESULTS: We enrolled 56 patients with sepsis and 20 control subjects with at least one blood sample being drawn from each patient. PDH activity and quantity in the sepsis group were significantly lower than the control group (P < 0.001). In multivariable linear regression adjusting for age, race, sex, and assay plate, the difference remained significant. Patients with sepsis who died had significantly lower PDH activity compared with those who survived (P = 0.03). CONCLUSIONS: PDH activity and quantity is decreased in peripheral blood mononuclear cells of humans with severe sepsis when compared with healthy control subjects, and may be associated with mortality. Whether decreased PDH activity plays a role in lactate metabolism or whether pharmacologic modification of PDH activity may improve outcomes remains unknown.
RATIONALE: Rodent studies have shown that pyruvate dehydrogenase (PDH) levels are low in sepsis. This may cause cells to shift to anaerobic metabolism, resulting in increased lactate production. Alterations in PDH during sepsis have never been studied in humans. OBJECTIVES: The objective of this pilot study was to measure PDH activity and quantity in patients with severe sepsis. METHODS: We conducted a pilot case-control study at a single urban tertiary care center. We compared PDH activity and quantity between patients with severe sepsis admitted to the intensive care unit and healthy control subjects. PDH activity and quantity were measured in isolated peripheral blood mononuclear cells. We measured PDH activity and quantity in control subjects at baseline and in patients with sepsis at 0 (baseline), 24, 48, and 72 hours. MEASUREMENTS AND MAIN RESULTS: We enrolled 56 patients with sepsis and 20 control subjects with at least one blood sample being drawn from each patient. PDH activity and quantity in the sepsis group were significantly lower than the control group (P < 0.001). In multivariable linear regression adjusting for age, race, sex, and assay plate, the difference remained significant. Patients with sepsis who died had significantly lower PDH activity compared with those who survived (P = 0.03). CONCLUSIONS:PDH activity and quantity is decreased in peripheral blood mononuclear cells of humans with severe sepsis when compared with healthy control subjects, and may be associated with mortality. Whether decreased PDH activity plays a role in lactate metabolism or whether pharmacologic modification of PDH activity may improve outcomes remains unknown.
Authors: Michael W Donnino; Erin Carney; Michael N Cocchi; Ian Barbash; Maureen Chase; Nina Joyce; Peter P Chou; Long Ngo Journal: J Crit Care Date: 2010-06-19 Impact factor: 3.425
Authors: Lars W Andersen; Xiaowen Liu; Teng J Peng; Tyler A Giberson; Kamal R Khabbaz; Michael W Donnino Journal: Shock Date: 2015-03 Impact factor: 3.454
Authors: Lars W Andersen; Julie Mackenhauer; Jonathan C Roberts; Katherine M Berg; Michael N Cocchi; Michael W Donnino Journal: Mayo Clin Proc Date: 2013-10 Impact factor: 7.616
Authors: Quincy Siu-Chung Chu; Randeep Sangha; Jennifer Spratlin; Larissa J Vos; John R Mackey; Alexander J B McEwan; Peter Venner; Evangelos D Michelakis Journal: Invest New Drugs Date: 2015-03-13 Impact factor: 3.850
Authors: Mehmet Akif Karamercan; Scott L Weiss; Jose Paul Perales Villarroel; Yuxia Guan; Evan Werlin; Ronald Figueredo; Lance B Becker; Carrie Sims Journal: Shock Date: 2013-12 Impact factor: 3.454
Authors: Bryan D Kraft; Lingye Chen; Hagir B Suliman; Claude A Piantadosi; Karen E Welty-Wolf Journal: Crit Care Med Date: 2019-05 Impact factor: 7.598
Authors: Mathias Johan Holmberg; Ari Moskowitz; Parth Vijay Patel; Anne Victoria Grossestreuer; Amy Uber; Nikola Stankovic; Lars Wiuff Andersen; Michael William Donnino Journal: J Crit Care Date: 2017-08-16 Impact factor: 3.425
Authors: Ari Moskowitz; Lars W Andersen; David T Huang; Katherine M Berg; Anne V Grossestreuer; Paul E Marik; Robert L Sherwin; Peter C Hou; Lance B Becker; Michael N Cocchi; Pratik Doshi; Jonathan Gong; Ayan Sen; Michael W Donnino Journal: Crit Care Date: 2018-10-29 Impact factor: 9.097
Authors: Veli Bakalov; Laura Reyes-Uribe; Rahul Deshpande; Abigail L Maloy; Steven D Shapiro; Derek C Angus; Chung-Chou H Chang; Laurence Le Moyec; Stacy Gelhaus Wendell; Ata Murat Kaynar Journal: PLoS One Date: 2020-11-05 Impact factor: 3.240